Design Therapeutics, Inc. Common Stock (DSGN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 55
- Market Cap
- $917M
About Design Therapeutics, Inc. Common Stock
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
SentiSense also tracks daily options readings for Design Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Design Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.